$24.51
12.12% yesterday
Nasdaq, Apr 28, 10:15 pm CET
ISIN
US0008991046
Symbol
ADMA
Sector
Industry

ADMA Biologics, Inc. Stock price

$24.51
+4.25 20.98% 1M
+8.08 49.18% 6M
+7.36 42.92% YTD
+17.93 272.49% 1Y
+22.62 1,196.83% 3Y
+21.58 736.52% 5Y
+16.00 188.01% 10Y
Nasdaq, Closing price Mon, Apr 28 2025
+2.65 12.12%
ISIN
US0008991046
Symbol
ADMA
Sector
Industry

Key metrics

Market capitalization $5.85b
Enterprise Value $5.83b
P/E (TTM) P/E ratio 30.28
EV/FCF (TTM) EV/FCF 52.75
EV/Sales (TTM) EV/Sales 13.66
P/S ratio (TTM) P/S ratio 13.71
P/B ratio (TTM) P/B ratio 16.62
Revenue growth (TTM) Revenue growth 65.15%
Revenue (TTM) Revenue $426.45m
EBIT (operating result TTM) EBIT $138.98m
Free Cash Flow (TTM) Free Cash Flow $110.45m
Cash position $103.15m
EPS (TTM) EPS $0.81
P/E forward 35.69
P/S forward 11.79
EV/Sales forward 11.74
Short interest 6.82%
Show more

Is ADMA Biologics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

ADMA Biologics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a ADMA Biologics, Inc. forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a ADMA Biologics, Inc. forecast:

Buy
75%
Hold
25%

Financial data from ADMA Biologics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
426 426
65% 65%
100%
- Direct Costs 207 207
22% 22%
49%
219 219
148% 148%
51%
- Selling and Administrative Expenses 70 70
28% 28%
16%
- Research and Development Expense 1.81 1.81
45% 45%
0%
147 147
391% 391%
34%
- Depreciation and Amortization 8.05 8.05
3% 3%
2%
EBIT (Operating Income) EBIT 139 139
542% 542%
33%
Net Profit 198 198
800% 800%
46%

In millions USD.

Don't miss a Thing! We will send you all news about ADMA Biologics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ADMA Biologics, Inc. Stock News

Neutral
GlobeNewsWire
about 22 hours ago
Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity
Neutral
GlobeNewsWire
22 days ago
Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain
Neutral
Investors Business Daily
25 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
More ADMA Biologics, Inc. News

Company Profile

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Head office United States
CEO Adam Grossman
Employees 685
Founded 2004
Website www.admabiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today